Home LiteratureArticle Details
PMID: 18460596 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat.

American journal of physiology. Endocrinology and metabolism ·Vol. 295 ·No. 1 ·2008-07-00 ·Pages E103-9

Whaley-Connell A, Habibi J, Cooper SA, Demarco VG, Hayden MR, Stump CS, Link D, Ferrario CM, Sowers JR

Abstract

Angiotensin II (Ang II) stimulation of the Ang type 1 receptor (AT(1)R) facilitates myocardial remodeling through NADPH oxidase-mediated generation of oxidative stress. Components of the renin-angiotensin system constitute an autocrine/paracrine unit in the myocardium, including renin, which is the rate-limiting step in the generation of Ang II. This investigation sought to determine whether cardiac oxidative stress and cellular remodeling could be attenuated by in vivo renin inhibition and/or AT(1)R blockade in a rodent model of chronically elevated tissue Ang II levels, the transgenic (mRen2)27 rat (Ren2). The Ren2 overexpresses the mouse renin transgene with resultant hypertension, insulin resistance, and cardiovascular damage. Young (6- to 7-wk-old) heterozygous (+/-) male Ren2 and age-matched Sprague-Dawley rats were treated with the renin inhibitor aliskiren, which has high preferential affinity for human and mouse renin, an AT(1)R blocker, irbesartan, or placebo for 3 wk. Myocardial NADPH oxidase activity and immunostaining for NADPH oxidase subunits and 3-nitrotyrosine were evaluated and remodeling changes assessed by light and transmission electron microscopy. Blood pressure, myocardial NADPH oxidase activity and subunit immunostaining, 3-nitrotyrosine, perivascular fibrosis, mitochondrial content, and markers of activity were significantly increased in Ren2 compared with SD littermates. Both renin inhibition and blockade of the AT(1)R significantly attenuated cardiac functional and structural alterations, although irbesartan treatment resulted in greater reductions of both blood pressure and markers of oxidative stress. Collectively, these data suggest that both reduce changes driven, in part, by Ang II-mediated increases in NADPH oxidase and, in part, increases in blood pressure.

MeSH Terms
Amides/pharmacology Angiotensin II Type 1 Receptor Blockers/pharmacology Animals Animals, Genetically Modified Antihypertensive Agents/pharmacology Biphenyl Compounds/pharmacology Blood Pressure/drug effects,physiology Fumarates/pharmacology Irbesartan Male Myocardium/metabolism NADPH Oxidases/metabolism Oxidative Stress/drug effects,physiology Rats Rats, Sprague-Dawley Receptor, Angiotensin, Type 1/metabolism Renin/antagonists & inhibitors Tetrazoles/pharmacology Tyrosine/analogs & derivatives,metabolism Ventricular Remodeling/drug effects,physiology
Chemicals
Amides Angiotensin II Type 1 Receptor Blockers Antihypertensive Agents Biphenyl Compounds Fumarates Receptor, Angiotensin, Type 1 Tetrazoles 3-nitrotyrosine Tyrosine aliskiren NADPH Oxidases Renin Irbesartan
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Whaley-Connell Adam
The University of Missouri School of Medicine, Department of Medicine, Columbia, Missouri, USA.
Habibi Javad
Cooper Shawna A
Demarco Vincent G
Hayden Melvin R
Stump Craig S
Link Daniel
Ferrario Carlos M
Sowers James R
References (46)
46 references, click to expand
  1. Spironolactone improves angiotensin-induced vascular changes and oxidative stress.
    Hypertension. 2002 Oct;40(4):504-10 PMID: 12364354
  2. Association of RhoGDIalpha with Rac1 GTPase mediates free radical production during myocardial hypertrophy.
    Cardiovasc Res. 2006 Jul 15;71(2):342-51 PMID: 16698001
  3. Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis.
    Hypertension. 2004 Feb;43(2):499-503 PMID: 14699000
  4. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts.
    Cardiovasc Res. 1998 Nov;40(2):352-63 PMID: 9893729
  5. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats.
    Diabetologia. 2007 Nov;50(11):2398-404 PMID: 17828524
  6. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Am J Hypertens. 2007 Jan;20(1):11-20 PMID: 17198906
  7. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
    Endocrinology. 2007 Aug;148(8):3773-80 PMID: 17494996
  8. Increased aortic NADPH oxidase activity in rats with genetically high angiotensin-converting enzyme levels.
    Hypertension. 2005 Dec;46(6):1362-7 PMID: 16230508
  9. Redox regulation of angiotensin II signaling in the heart.
    J Cell Mol Med. 2004 Jan-Mar;8(1):144-52 PMID: 15090271
  10. Hypertension, angiotensin II, and oxidative stress.
    N Engl J Med. 2002 Jun 20;346(25):1999-2001 PMID: 12075063
  11. Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression.
    J Clin Invest. 1994 Jun;93(6):2372-8 PMID: 8200970
  12. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    Hypertension. 2007 Feb;49(2):276-84 PMID: 17159081
  13. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin.
    Chem Biol. 2000 Jul;7(7):493-504 PMID: 10903938
  14. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat.
    Am J Physiol Renal Physiol. 2006 Dec;291(6):F1308-14 PMID: 16788142
  15. NADPH oxidase is involved in angiotensin II-induced apoptosis in H9C2 cardiac muscle cells: effects of apocynin.
    Free Radic Biol Med. 2006 Jan 15;40(2):236-46 PMID: 16413406
  16. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function.
    Circ Res. 2003 Feb 21;92(3):322-9 PMID: 12595345
  17. Reduction in left ventricular messenger RNA for transforming growth factor beta(1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 Rat.
    Hypertension. 2000 Nov;36(5):747-54 PMID: 11082138
  18. Human cells are protected from mitochondrial dysfunction by complementation of DNA products in fused mitochondria.
    Nat Genet. 2001 Jul;28(3):272-5 PMID: 11431699
  19. Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat.
    Am J Physiol Endocrinol Metab. 2007 Jul;293(1):E355-63 PMID: 17440033
  20. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats.
    Hypertension. 2005 Sep;46(3):569-76 PMID: 16103264
  21. Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms.
    Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):949-56 PMID: 10764658
  22. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1.
    Nature. 1991 Oct 17;353(6345):668-70 PMID: 1922386
  23. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy.
    Circ Res. 2003 Oct 31;93(9):802-5 PMID: 14551238
  24. Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats.
    Endocrinology. 2007 May;148(5):2181-8 PMID: 17317778
  25. Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype.
    Circ Res. 1993 Sep;73(3):413-23 PMID: 8348686
  26. Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27.
    J Mol Med (Berl). 2004 Oct;82(10):678-87 PMID: 15322702
  27. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice.
    Circulation. 2002 Jan 22;105(3):293-6 PMID: 11804982
  28. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
    J Hypertens. 2007 Jan;25(1):217-26 PMID: 17143194
  29. The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats.
    Br J Pharmacol. 2004 Jan;141(1):105-13 PMID: 14656807
  30. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits.
    Circ Res. 2006 Mar 31;98(6):730-42 PMID: 16574914
  31. Myocardial remodeling in hypertensive Ren-2 transgenic rats.
    Hypertension. 1995 Jan;25(1):98-104 PMID: 7843762
  32. Vascular endothelial growth factor induces manganese-superoxide dismutase expression in endothelial cells by a Rac1-regulated NADPH oxidase-dependent mechanism.
    FASEB J. 2001 Nov;15(13):2548-50 PMID: 11641265
  33. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats.
    J Hypertens. 2005 Feb;23(2):417-26 PMID: 15662231
  34. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy.
    J Mol Cell Cardiol. 2003 Jul;35(7):851-9 PMID: 12818576
  35. Angiotensin and bradykinin peptides in the TGR(mRen-2)27 rat.
    Hypertension. 1995 May;25(5):1014-20 PMID: 7737708
  36. Mechanical stretch and angiotensin II differentially upregulate the renin-angiotensin system in cardiac myocytes In vitro.
    Circ Res. 1999 Jul 23;85(2):137-46 PMID: 10417395
  37. Differential gene expression of renin and angiotensinogen in the TGR(mREN-2)27 transgenic rat.
    Hypertension. 1995 Apr;25(4 Pt 1):570-80 PMID: 7721400
  38. Oxidative damage and mitochondrial decay in aging.
    Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10771-8 PMID: 7971961
  39. Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II.
    J Am Coll Cardiol. 2003 Feb 19;41(4):666-73 PMID: 12598081
  40. Ontogenetic regulation of mouse Ren-2d renin gene in transgenic hypertensive rats, TGR(mREN2)27.
    Am J Physiol. 1993 Nov;265(5 Pt 1):E699-707 PMID: 8238495
  41. Oxygen, oxidative stress, hypoxia, and heart failure.
    J Clin Invest. 2005 Mar;115(3):500-8 PMID: 15765131
  42. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion.
    J Clin Invest. 2006 Apr;116(4):1063-70 PMID: 16585966
  43. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase.
    Hypertension. 2003 Aug;42(2):206-12 PMID: 12847113
  44. Mitochondria harbouring mutant mtDNA--a cuckoo in the nest?
    Biol Chem. 1999 Jul-Aug;380(7-8):871-7 PMID: 10494836
  45. Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure.
    Circ Res. 2001 Feb 16;88(3):298-304 PMID: 11179197
  46. Role of mitochondrial dysfunction in insulin resistance.
    Circ Res. 2008 Feb 29;102(4):401-14 PMID: 18309108
Article Info
Journal
American journal of physiology. Endocrinology and metabolism
Abbr.
Am J Physiol Endocrinol Metab
ISSN
0193-1849
Published
2008-07-00
Epub
2008-00-06
Pages
E103-9
Language
English
Region
United States
NLM ID
100901226
PMCID
PMC2493592
Subset
IM
Grants
NHLBI NIH HHS · P01 HL051952 · United States
NHLBI NIH HHS · R01-HL-73101-01A1 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]